Privium Fund Management B.V. bought a new stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 27,691 shares of the company's stock, valued at approximately $295,000. Privium Fund Management B.V. owned 0.12% of UroGen Pharma as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. GSA Capital Partners LLP acquired a new stake in shares of UroGen Pharma during the 3rd quarter worth about $249,000. Intech Investment Management LLC acquired a new stake in shares of UroGen Pharma during the third quarter valued at about $155,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of UroGen Pharma by 9.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 90,493 shares of the company's stock worth $1,149,000 after acquiring an additional 7,576 shares during the last quarter. FMR LLC raised its position in UroGen Pharma by 575.1% in the third quarter. FMR LLC now owns 23,090 shares of the company's stock valued at $293,000 after purchasing an additional 19,670 shares during the period. Finally, BNP Paribas Financial Markets grew its position in UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock valued at $109,000 after acquiring an additional 5,890 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company's stock.
Insider Transactions at UroGen Pharma
In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of the business's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the sale, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.10% of the company's stock.
UroGen Pharma Stock Performance
NASDAQ URGN traded up $0.11 during trading hours on Friday, hitting $12.13. The company had a trading volume of 468,344 shares, compared to its average volume of 492,295. The business has a 50 day moving average of $10.54 and a 200-day moving average of $11.57. The company has a market cap of $559.12 million, a PE ratio of -3.85 and a beta of 1.12. UroGen Pharma Ltd. has a 1-year low of $9.03 and a 1-year high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The firm had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. As a group, equities research analysts expect that UroGen Pharma Ltd. will post -3.12 EPS for the current year.
Analyst Upgrades and Downgrades
URGN has been the subject of a number of analyst reports. HC Wainwright lowered their price objective on UroGen Pharma from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. D. Boral Capital reiterated a "buy" rating and set a $25.00 price target on shares of UroGen Pharma in a report on Monday, March 10th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $38.20.
Check Out Our Latest Analysis on UroGen Pharma
UroGen Pharma Profile
(
Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Featured Articles
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
